文献速递产科母胎医学

1型糖尿病妊娠中持续葡萄糖监测:目标范围内时间小幅增加改善母婴结局

Continuous glucose monitoring in pregnancies with type 1 diabetes: small increases in time-in-range improve maternal and perinatal outcomes.
PubMed 文献 · Am J Obstet Gynecol · 2024-01-17

这项多中心回顾性队列研究纳入2020至2022年加州大学5个中心91例使用持续葡萄糖监测的1型糖尿病孕妇,分析目标范围内时间与先兆子痫及大于胎龄儿的关系。调整分析显示,孕12周时目标范围内时间每增加5个单位,先兆子痫风险降低45%(调整风险比0.55,95%CI 0.30-0.99),大于胎龄儿风险降低46%(调整风险比0.54,95%CI 0.29-0.99)。

要点

  • 孕12周目标范围内时间每增加5个单位,先兆子痫风险降低45%(调整风险比0.55,95%CI 0.30-0.99)。
  • 孕12周目标范围内时间每增加5个单位,大于胎龄儿风险降低46%(调整风险比0.54,95%CI 0.29-0.99)。
  • 血压正常孕妇在几乎所有时间点的目标范围内时间均显著高于先兆子痫孕妇。

核心结论

  • 较高的目标范围内时间与较低的先兆子痫和大于胎龄儿风险相关,该关联在妊娠早期即可观察到。
  • 孕12周时目标范围内时间每增加5个单位,先兆子痫和大于胎龄儿风险约降低50%。
  • 这些发现可用于咨询特定目标范围内时间值下的妊娠并发症风险,并鼓励患者即使小幅改善目标范围内时间也可能对妊娠结局产生显著影响。
  • 需要更大规模的研究进一步探索这些发现并确定降低围产期并发症率的最佳目标范围内时间。

研究设计与样本

  • 多中心回顾性队列研究,纳入2020至2022年在加州大学5个中心分娩的所有使用持续葡萄糖监测的1型糖尿病孕妇。
  • 仅纳入持续葡萄糖监测目标范围设定为70至140 mg/dL(±10 mg/dL)者。
  • 共纳入91例患者,大多数使用胰岛素泵(81%),无糖尿病微血管病变者占72%。
  • 1型糖尿病诊断中位时间为16年,围受孕期血红蛋白A1c中位数为6.7%。
  • 目标范围内时间(%)在孕12、16、20、24、28和32周记录。

主要发现

  • 与先兆子痫孕妇相比,血压正常孕妇在几乎所有时间点的目标范围内时间均显著更高。
  • 与大于胎龄儿孕妇相比,正常出生体重婴儿孕妇的目标范围内时间呈现相似模式。
  • 调整微血管病变和1型糖尿病病程后,孕12周目标范围内时间每增加5个单位,先兆子痫调整风险比为0.55(95%CI 0.30-0.99),大于胎龄儿调整风险比为0.54(95%CI 0.29-0.99)。

关键数值与推荐

  • 主要母体结局为先兆子痫,主要新生儿结局为大于胎龄儿(出生体重≥95百分位)。
  • 采用Kruskal-Wallis检验比较有无主要结局者的目标范围内时间中位数。
  • 采用对数二项回归获得风险比,并调整微血管病变和1型糖尿病病程。

临床怎么用

  • 这些发现可用于咨询患者特定目标范围内时间值下的妊娠并发症风险。
  • 可鼓励患者即使目标范围内时间小幅改善也可能对妊娠结局产生显著影响。

局限性

  • 需要更大规模的研究进一步探索这些发现并确定降低围产期并发症率的最佳目标范围内时间。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Continuous glucose monitors provide detailed information regarding glycemic control in pregnant patients with type 1 diabetes. Little data have been published examining the association between continuous glucose monitor parameters and perinatal outcomes among gravidas with type 1 diabetes using continuous glucose monitors. OBJECTIVE: This study aimed to examine the association between perinatal outcomes and time-in-range as assessed by continuous glucose monitors used in pregnant individuals with type 1 diabetes. We hypothesized that higher time-in-range would be associated with lower risk of adverse perinatal outcomes. STUDY DESIGN: This multicenter retrospective cohort study included all gravidas with type 1 diabetes using continuous glucose monitors who delivered from 2020 to 2022 at 5 University of California sites. Only those with continuous glucose monitor target range set to 70 to 140 mg/dL (±10 mg/dL) were included. Time-in-range (%) was recorded at 12, 16, 20, 24, 28, and 32 weeks. The primary maternal and neonatal outcomes were preeclampsia and large for gestational age, defined as birthweight ≥95th percentile. Kruskal-Wallis tests were used to compare median time-in-range between those with and without the primary outcomes. Log-binomial regression was used to obtain risk ratios, with adjustment for microvascular disease and years with type 1 diabetes. RESULTS: A total of 91 patients were included. Most used an insulin pump (81%) and did not have diabetic microvascular disease (72%). Median time since diagnosis of type 1 diabetes was 16 years, and median periconception hemoglobin A1c was 6.7%. Compared with those with preeclampsia, normotensive gravidas had significantly higher time-in-range at nearly every time point. A similar pattern was observed for those with normal-birthweight infants compared with large-for-gestational-age infants. On adjusted analyses, every 5-unit increase in time-in-range at 12 weeks was associated with 45% and 46% reductions in the risks of preeclampsia and large for gestational age, respectively (preeclampsia: adjusted risk ratio, 0.55; 95% confidence interval, 0.30-0.99; large for gestational age: adjusted risk ratio, 0.54; 95% confidence interval, 0.29-0.99). CONCLUSION: Higher time-in-range is associated with lower risk of preeclampsia and large for gestational age. This association is observed early in gestation, when each 5-unit increase in time-in-range is associated with ∼50% reduction in the risk of these complications. These findings can be used to counsel patients regarding the risk of pregnancy complications at specific time-in-range values, and to encourage patients that even small improvements in time-in-range can have significant impact on pregnancy outcomes. Larger studies are needed to further explore these findings and to identify optimal time-in-range to reduce perinatal complication rates.

来源:Am J Obstet Gynecol,查看原文。版权归原作者所有。

引用

  1. Sobhani NC, Goemans S, Nguyen A, et al. Continuous glucose monitoring in pregnancies with type 1 diabetes: small increases in time-in-range improve maternal and perinatal outcomes. Am J Obstet Gynecol. 2024. PMID: 38242337. doi:10.1016/j.ajog.2024.01.010

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。